The Quantellect read.As of Nov 19, 2026, 3 active firms cover Bausch Health Companies Inc: 0 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets are tightly clustered, $7.00 to $9.00, so the covering firms are broadly aligned. The average target of $8.00 sits 8% below the current $8.73. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 5% this year and 0% next, consensus EPS building from about $0.79 next quarter toward $4.34 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Neutral
Strong Buy00%
Buy00%
Neutral3100%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$8.00
-8.4% downside
Average target across 3 active firms as of Nov 19, 2026 vs $8.73 current
Highest Target$9.00
Average Target$8.00
Lowest Target$7.00
Detailed analyst forecasts for BHC
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 0 of 3 active firms rate BHC a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BHC EPS & revenue forecast
EPS · NEXT QUARTER
$0.79
Range $0.71 – $0.87 · 4 analysts · +2% YoY
Next period, 4 analysts expect Bausch Health Companies Inc to earn $0.79 a share (range $0.71 – $0.87), versus $0.78 a year earlier. Full-year consensus is $4.91, growing to $4.34 the year after.
REVENUE · NEXT QUARTER
$2.5B
Range $2.5B – $2.5B · 4 analysts · +2% YoY
Revenue is expected to reach $2.5B (range $2.5B – $2.5B), +2.0% year-over-year. Full-year consensus is $11.0B, rising to $11.0B next year.
Top analysts covering Bausch Health Companies Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BHC.
#1
Jason Gerberry
B of A Securities · Rank #160
Sell
$5.00-42.7% to target
Overall win rate
47%
+ Follow
#2
DM
Douglas Miehm
RBC Capital · Rank #263
Neutral
$9.00+3.1% to target
Overall win rate
43%
+ Follow
#3
GS
Glen Santangelo
Barclays
Neutral
$7.00-19.8% to target
Coverage
—
+ Follow
#4
MF
Michael Freeman
Raymond James
Neutral
$8.00-8.4% to target
Coverage
—
+ Follow
#5
MN
Michael Nedelcovych
TD Cowen
Neutral
$7.00-19.8% to target
Coverage
—
+ Follow
BHC stock forecast FAQ
What is BHC's average 12-month price target?+
The 3 active firms with a live target average $8.00 for Bausch Health Companies Inc over the next 12 months, ranging from a $9.00 high to a $7.00 low, as of Nov 19, 2026.
Is BHC stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 3 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BHC?+
The Street-high target is $9.00 (RBC Capital), and the Street-low is $7.00 (Barclays). The average of all 3 active-firm targets is $8.00.
How many active Wall Street firms cover BHC?+
3 active firms have a recognized rating on Bausch Health Companies Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BHC?+
Among analysts who currently cover BHC, Jason Gerberry of B of A Securities has the strongest overall Quantellect track record (Rank #160). Their current call is Sell with a $5.00 target.
What is Bausch Health Companies Inc's projected EPS for next quarter?+
The consensus estimate is $0.79 per share (range $0.71 – $0.87) across 4 analysts. Full-year EPS is projected at $4.91, rising to $4.34 the following year.
How much revenue is Bausch Health Companies Inc expected to report next quarter?+
Consensus revenue is $2.5B (range $2.5B – $2.5B). Full-year revenue is projected at $11.0B, growing to $11.0B next year.
Have analysts been upgrading or downgrading BHC lately?+
As of Nov 19, 2026, 0 of 3 active firms rate BHC a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BHC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.